AstraZeneca PLC
AZN92.900USD
+0.450+0.49%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
288.12BCap. mercado
30.64P/E TTM
Más Datos de AstraZeneca PLC Compañía
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Información de AstraZeneca PLC
Símbolo de cotizaciónAZN
Nombre de la empresaAstraZeneca PLC
Fecha de salida a bolsaSep 21, 2007
Director ejecutivoDunoyer (Marc)
Número de empleados94300
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 21
Dirección1 Francis Crick Avenue
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCB2 0AA
Teléfono442073045000
Sitio Webhttps://www.astrazeneca.com/
Símbolo de cotizaciónAZN
Fecha de salida a bolsaSep 21, 2007
Director ejecutivoDunoyer (Marc)
Ejecutivos de AstraZeneca PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Otro
6.33B
45.89%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
6.32B
45.84%
Europe
3.07B
22.23%
EX-China
2.04B
14.82%
China
1.71B
12.40%
Established ROW
1.31B
9.53%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Otro
6.33B
45.89%
Estadísticas de accionistas
Actualizado: mar., 25 de nov
Actualizado: mar., 25 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
Otro
95.15%
Accionistas
Accionistas
Proporción
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
Otro
95.15%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
8.78%
Investment Advisor/Hedge Fund
5.84%
Research Firm
1.11%
Hedge Fund
0.69%
Bank and Trust
0.19%
Pension Fund
0.06%
Venture Capital
0.03%
Family Office
0.02%
Family Office
0.02%
Otro
83.26%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
2038
518.15M
17.29%
+1.97M
2025Q3
2089
516.24M
17.34%
-2.62M
2025Q2
2062
519.46M
17.59%
-9.37M
2025Q1
2054
529.82M
17.91%
-25.96M
2024Q4
2001
537.38M
17.35%
+13.04M
2024Q3
1925
524.26M
17.32%
+244.85K
2024Q2
1912
524.03M
17.41%
+1.94M
2024Q1
1863
521.64M
17.31%
-15.18M
2023Q4
1837
514.30M
17.42%
-5.99M
2023Q3
1809
522.19M
17.30%
+4.27M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
PRIMECAP Management Company
41.20M
1.33%
+538.61K
+1.32%
Jun 30, 2025
Wellington Management Company, LLP
34.34M
1.11%
-1.29M
-3.63%
Jun 30, 2025
T. Rowe Price International Ltd
30.71M
0.99%
+3.43M
+12.56%
Jun 30, 2025
Capital International Investors
31.40M
1.01%
+119.42K
+0.38%
Jun 30, 2025
Managed Account Advisors LLC
21.15M
0.68%
-1.37M
-6.07%
Jun 30, 2025
Fisher Investments
20.70M
0.67%
+530.52K
+2.63%
Jun 30, 2025
Fidelity Management & Research Company LLC
18.04M
0.58%
-944.35K
-4.97%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.24M
0.68%
-8.57M
-28.75%
Jun 30, 2025
Sanders Capital, LLC
14.53M
0.47%
-542.12K
-3.60%
Jun 30, 2025
Putnam Investment Management, L.L.C.
12.48M
0.4%
+184.41K
+1.50%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Nombre
Proporción
Amplify Weight Loss Drug & Treatment ETF
5.58%
VanEck Pharmaceutical ETF
4.97%
Invesco Nasdaq Biotechnology ETF
4.81%
ProShares Ultra Nasdaq Biotechnology
4.81%
Parnassus Value Select ETF
4.66%
Invesco QQQ Low Volatility ETF
4.19%
Roundhill GLP-1 & Weight Loss ETF
3.36%
Abacus FCF International Leaders ETF
3.28%
Global X Aging Population ETF
3.2%
Franklin Genomic Advancements ETF
3.05%
Ver más
Amplify Weight Loss Drug & Treatment ETF
Proporción5.58%
VanEck Pharmaceutical ETF
Proporción4.97%
Invesco Nasdaq Biotechnology ETF
Proporción4.81%
ProShares Ultra Nasdaq Biotechnology
Proporción4.81%
Parnassus Value Select ETF
Proporción4.66%
Invesco QQQ Low Volatility ETF
Proporción4.19%
Roundhill GLP-1 & Weight Loss ETF
Proporción3.36%
Abacus FCF International Leaders ETF
Proporción3.28%
Global X Aging Population ETF
Proporción3.2%
Franklin Genomic Advancements ETF
Proporción3.05%
Dividendos
Un total de
20.90B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Jul 29, 2025
AZN.NB Final Cash Dividend of gross USD 0.515 paid on Sep 08, 2025 going ex on Aug 08, 2025
Aug 08, 2025
Sep 08, 2025
Aug 08, 2025
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de AstraZeneca PLC?
Los cinco principales accionistas de AstraZeneca PLC son:
PRIMECAP Management Company posee 41.20M acciones, lo que representa el 1.33% del total de acciones.
Wellington Management Company, LLP posee 34.34M acciones, lo que representa el 1.11% del total de acciones.
T. Rowe Price International Ltd posee 30.71M acciones, lo que representa el 0.99% del total de acciones.
Capital International Investors posee 31.40M acciones, lo que representa el 1.01% del total de acciones.
Managed Account Advisors LLC posee 21.15M acciones, lo que representa el 0.68% del total de acciones.
PRIMECAP Management Company posee 41.20M acciones, lo que representa el 1.33% del total de acciones.
Wellington Management Company, LLP posee 34.34M acciones, lo que representa el 1.11% del total de acciones.
T. Rowe Price International Ltd posee 30.71M acciones, lo que representa el 0.99% del total de acciones.
Capital International Investors posee 31.40M acciones, lo que representa el 1.01% del total de acciones.
Managed Account Advisors LLC posee 21.15M acciones, lo que representa el 0.68% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de AstraZeneca PLC?
Los tres principales tipos de accionista de AstraZeneca PLC son:
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
¿Cuántas instituciones poseen acciones de AstraZeneca PLC (AZN)?
A fecha de 2025Q4, 2038 instituciones poseen acciones de AstraZeneca PLC, con un valor de mercado combinado de aproximadamente 518.15M, lo que representa el 17.29% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.05%.
¿Cuál es la mayor fuente de ganancias de AstraZeneca PLC?
El FY2025Q2, el segmento empresarial Farxiga generó la ganancia más alta para AstraZeneca PLC, ascendiendo a 2.15B y representando el 15.59% de la ganancia total.
